Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.64 |
| ▸ | MAOA | P21397 | 10/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469916 | 1.00 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL395053 | 0.87 | HTT (0.59) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL279937 | 0.78 | EPHX2 (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL299571 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL3599640 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL18307137 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL5751107 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL6015836 | 0.78 | MAOB (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL4219649 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL6754956 | 0.75 | KIF11 (0.68) | MAOBMAOAEPHX2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-6011033-A | ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION | KOWA CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| US-5885987-A | ANTIHISTAMINE AGENT FOR TREATING ASTHMA, ANTILEUKOTRIENE AGENT, ANTIALLERGENS | KOWA CO., LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5756518-A | EXHIBITS ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION; IS USEFUL IN TREATMENT OF ASTHMA | KOWA CO., LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0799826-A1 | Heteroaryl substituted phenylene derivatives, their preparation and their use as leukotriene receptor antagonists | KOWA CO. LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-4535079-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS; VASODILATORS | MEDIOLANUM FARMACEUTICI S.R.L. (IT) | 1985-08-13 | — | — | US | disclosed |
| EP-0106816-A2 | Alkanolaminoxy derivatives of 3,4-dihydro-2H-1,4-benzothiazin-3-one, their production process, and their pharmaceutical use | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | MAOB 1349/4885MAOA 1461/4885EPHX2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.